Delivering on patient insights, wants, and needs through continuous innovation
Why are we leaders in HIV innovation? Because we listen. We collect insights from people living with HIV around the world that informs our approach to the discovery and development of innovative new treatment and prevention options.
Today, HIV treatments allow people living with HIV to suppress their virus to undetectable levels, but we won’t stop there – we want to better the quality of life for people living with and impacted by HIV. To do that we prioritise developing medicines that fit their lifestyle. We know that the needs of people living with HIV change over time, and we’re exploring new ways of treating and preventing HIV through new approaches in how we target the virus and deliver medicine.
How do we develop new options for the HIV community?
The process of identifying, creating, and developing generally well-tolerated and effective HIV medicines is complex and requires ongoing collaboration between different research teams. Our facility in Branford, Connecticut in the US is one of the only HIV-dedicated research centres and allows our scientists to work together to discover and develop potential new HIV treatment and prevention candidates with a unified purpose; to leave no person living with HIV behind and end the HIV epidemic.
Home to over 30 researchers, our scientists talk through our innovation and discovery process.
Can we go faster? How we accelerate and deliver on patient needs
“When we first started to look at our overall drug development process, we saw timelines around 9.2 years. With the way we work now in Branford and ViiV, we can potentially decrease it by 3.5 years”
Although the clinical development process is complex and may take many years, our teams at Branford are working to advance the speed at which we discover and develop new medicines. Developing a new medicine requires collaboration between scientists from multiple disciplines to design and deliver new molecules. There are many people involved from the discovery and screening process through to the market launch. However, at Branford these different specialties are all housed under one roof, breaking down silos and fostering collaboration.
At Branford, molecules are designed and researched for activity and optimal drug-like qualities. Once this process is complete, the candidate drug compounds are seamlessly transitioned to the early development team on site. This accelerates the overall progress and promotes ongoing partnership with our colleagues in-house.
You can learn more about each step of the drug development process, which starts in Branford, below.
Committed to the science, bound by our mission
We’ve come a long way in our mission to end the HIV epidemic, but there is still work to be done. We will continue to listen to the needs of people living with HIV to create new innovative options that not only suppress the virus to undetectable levels or prevent it from being acquired, but also contribute to a good quality of life.
YOU MAY ALSO BE INTERESTED IN
It is now established that if you’re on treatment and have an undetectable viral load, you cannot pass on HIV through sex. Undetectable = Untransmittable, or U=U. This simple equation has profound implications for everyone living with HIV, and for economies and governments around the world.